IMMY Stock News 6.79 05/09/2014 19:03:55 Imprimis Pharmaceuticals
Post# of 273322
Posted On: 05/09/2014 8:03:57 PM
Imprimis Pharmaceuticals Inc (IMMY) 6.79 $IMMY
Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress
PR Newswire - Tue Apr 22, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today its attendance and physicians' presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress in Boston from April 25-29, 2014.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 03, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference
PR Newswire - Tue Mar 25, 5:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS(TM))/Dulaney Winter Meeting
PR Newswire - Tue Feb 25, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS(TM)). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS (http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.
Imprimis elects Randle House as VP of Pharmacy Operations
M2 - Thu Feb 20, 5:15AM CST
US-based specialist pharmaceutical company Imprimis Pharmaceuticals Inc (IMMY:NasdaqCM) reported on Wednesday the appointment of Randle House as vice president (VP) of its Pharmacy Operations.
Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations
PR Newswire - Tue Feb 11, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that it has come to an agreement to acquire Pharmacy Creations LLC (www.pharmacycreations.com), a premier, state-of-the-art compounding pharmacy located in Randolph, New Jersey. This acquisition would permit the Company to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting
PR Newswire - Tue Jan 28, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless(TM) campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
PR Newswire - Mon Dec 09, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a pharmaceutical company focused on commercial development of novel drug formulations and drug delivery technologies announced their intention today to pursue a compounding pharmacy strategy in 2014 and beyond.
Imprimis Optimistic After Congressional Passage of the Drug Quality and Security Act
PR Newswire - Tue Nov 19, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today voiced support for the U.S. Senate's approval of the Drug Quality and Security Act (H.R. 3204), which clarifies and strengthens the regulatory framework for compounding pharmacies.
Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek as Vice-President of Commercialization for its Ophthalmology Division
PR Newswire - Tue Nov 12, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced the hiring of John Saharek to serve as Vice-President of Commercialization for Ophthalmology.
Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
PR Newswire - Fri Nov 08, 12:36PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, November 16-19 (Booth #5058). Imprimis' presence at this conference is primarily to continue the pre-launch assessments of two of its proprietary ophthalmic sterile injectable compounded formulations, which Imprimis expects to make available to the ophthalmology community in 2014.
OTC Daily Alert Stock Watch - Imprimis Pharmaceuticals, Inc (NASDAQ: IMMY)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
PR Newswire - Wed Aug 28, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress
PR Newswire - Tue Apr 22, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today its attendance and physicians' presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress in Boston from April 25-29, 2014.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 03, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference
PR Newswire - Tue Mar 25, 5:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS(TM))/Dulaney Winter Meeting
PR Newswire - Tue Feb 25, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS(TM)). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS (http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.
Imprimis elects Randle House as VP of Pharmacy Operations
M2 - Thu Feb 20, 5:15AM CST
US-based specialist pharmaceutical company Imprimis Pharmaceuticals Inc (IMMY:NasdaqCM) reported on Wednesday the appointment of Randle House as vice president (VP) of its Pharmacy Operations.
Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations
PR Newswire - Tue Feb 11, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that it has come to an agreement to acquire Pharmacy Creations LLC (www.pharmacycreations.com), a premier, state-of-the-art compounding pharmacy located in Randolph, New Jersey. This acquisition would permit the Company to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting
PR Newswire - Tue Jan 28, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless(TM) campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
PR Newswire - Mon Dec 09, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a pharmaceutical company focused on commercial development of novel drug formulations and drug delivery technologies announced their intention today to pursue a compounding pharmacy strategy in 2014 and beyond.
Imprimis Optimistic After Congressional Passage of the Drug Quality and Security Act
PR Newswire - Tue Nov 19, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today voiced support for the U.S. Senate's approval of the Drug Quality and Security Act (H.R. 3204), which clarifies and strengthens the regulatory framework for compounding pharmacies.
Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek as Vice-President of Commercialization for its Ophthalmology Division
PR Newswire - Tue Nov 12, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced the hiring of John Saharek to serve as Vice-President of Commercialization for Ophthalmology.
Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
PR Newswire - Fri Nov 08, 12:36PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, November 16-19 (Booth #5058). Imprimis' presence at this conference is primarily to continue the pre-launch assessments of two of its proprietary ophthalmic sterile injectable compounded formulations, which Imprimis expects to make available to the ophthalmology community in 2014.
OTC Daily Alert Stock Watch - Imprimis Pharmaceuticals, Inc (NASDAQ: IMMY)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
PR Newswire - Wed Aug 28, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
(0)
(0)